Trials / Terminated
TerminatedNCT00048750
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU
A Phase 3, Randomized,Double-Blind, Comparative Study of Micafungin (FK463) Versus Placebo as Preemptive Prophylactic Antifungal Therapy in Patients in the Intensive Care Unit
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Micafungin | IV |
| DRUG | Placebo | IV |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2003-06-01
- Completion
- 2003-06-01
- First posted
- 2002-11-08
- Last updated
- 2012-03-27
Locations
48 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00048750. Inclusion in this directory is not an endorsement.